Nanjing Pharmaceutical Co (SHSE:600713) Other Net Income (Loss) : ¥0 Mil (TTM As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Nanjing Pharmaceutical Co Other Net Income (Loss)?

Nanjing Pharmaceutical Co's Other Net Income (Loss) for the three months ended in Mar. 2024 was ¥0 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥0 Mil.

Nanjing Pharmaceutical Co's quarterly Other Net Income (Loss) declined from Sep. 2023 (¥0 Mil) to Dec. 2023 (¥-0 Mil) but then increased from Dec. 2023 (¥-0 Mil) to Mar. 2024 (¥0 Mil).

Nanjing Pharmaceutical Co Other Net Income (Loss) Historical Data

The historical data trend for Nanjing Pharmaceutical Co's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanjing Pharmaceutical Co Other Net Income (Loss) Chart

Nanjing Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Net Income (Loss)

Get a 7-Day Free Trial

Nanjing Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	-	-	-

Nanjing Pharmaceutical Co Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0 Mil.

Nanjing Pharmaceutical Co Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Nanjing Pharmaceutical Co's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanjing Pharmaceutical Co (SHSE:600713) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nanjing Pharmaceutical Co Ltd (SHSE:600713) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 486 Zhongshan East Road, Nanjing, Jiangsu, CHN, 210002

Website

http://www.guangyuyuan.com

Nanjing Pharmaceutical Co Ltd is engaged in the pharmaceutical service business.

Executives

Xiao Hong	senior management
Peng Yu Ping	senior management
She Ping	Supervisors
Jiang Xiao Jun	senior management
Teng Xue Wu	senior management
Zhou Jian Jun	senior management
Li Yi	Director
Huang Yan Li	Supervisors
Tang Jian Zhong	senior management
Zhang Yan Hui	senior management
Zhou Yao Ping	Director
Wang Hui Qing	senior management
He Jin Geng	senior management
Ding Feng Jun	Director
Liang Yu Tang	Director

Nanjing Pharmaceutical Co (SHSE:600713) Headlines

No Headlines